



# PATIENT ELIGIBILITY

## Task

Determine what populations of children will be targeted in the initial rollout.

## Overview

At this stage the Ministry of Health (MOH) can engage its stakeholders, such as policy-makers, clinicians, project and funding agencies, implementing partners, civil society organizations and nongovernmental organizations, to decide on the clinical aspects of the use of LPV/r pellets within their system.

## Patient Eligibility

Specifically, the MOH needs to decide whether the LPV/r pellets should only be considered for newly initiated patients, or whether to switch children under 3 years old who are currently doing well on NVP-containing regimens or other LPV/r formulations.

Country programs are encouraged to consider the following suggestions from the [Antiretroviral \(ARV\) Procurement Working Group](#) when articulating eligibility groups for LPV/r pellets, so as to target the pellets to those patients who need it most:

Patient Description	Patient Eligibility
<b>Patients to be optimized for LPV/r pellets</b>	<ul style="list-style-type: none"><li>• Patients currently on or needing LPV/r-containing regimens (1st or 2nd line) who cannot tolerate LPV/r solution and are not able to swallow LPV/r 100mg/25mg tablets whole.</li><li>• Patients &lt; 3 years old who are newly initiating antiretroviral treatment.</li></ul>
<b>Patients for whom transition to pellets may be delayed</b>	<ul style="list-style-type: none"><li>• Patients currently stable on an NVP- or efavirenz (EFV)-containing 1st-line regimen (i.e. viral suppression, or if viral load is not available, those who are clinically or immunologically stable).</li><li>• Patients tolerating LPV/r solution, if the program is able to maintain a sufficient supply of solution.</li></ul>
<b>Patients for whom LPV/r pellets should NOT be used</b>	<ul style="list-style-type: none"><li>• Patients weighing 10 kilograms or more AND are able to swallow LPV/r 100mg/25mg tablets whole.</li><li>• Patients &lt; 3 months old (until further information is available about safety and tolerability in this group).</li><li>• Newly initiating patients aged 3 years or older who may be initiated on an EFV-containing regimen.</li></ul>

**Additional  
recommendations for  
older children**

- Consider procurement of the LPV/r 100mg/25mg tablet for children weighing 10 kilograms or more who are able to swallow tablets whole.
- Consider adopting the recommendation to transition children aged 3 years or older who are on an LPV/r-containing 1st-line regimen and have maintained sustained viral suppression, to an EFV-based regimen.

## Additional Resources

[ARV Procurement Working Group Memorandum: Re: Available Supply of Paediatric LPV/r formulations and guidance for country procurement](#) [PDF, 259KB]: Memorandum from the ARV Procurement Working Group in April 2017 with information and guidance for country programs planning to procure LPV/r pellets or LPV/r solution. [2019 update](#). [PDF, 356KB]